Journal of Clinical Oncology
Articles in this Issue
A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated <i>BRAF</i> <sup>V600E</sup> -mutant metastatic colorectal cancer.
LBA3509 Background: The BRAF V600E mutation present in approximately 10% of metastatic colorectal cancer (mCRC) cases, con...
Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.
LBA5012 Background: There is a critical evidence gap on the relative benefits and harms of proton therapy (PT) compared wi...
Efficacy and safety of asandeutertinib versus osimertinib as first-line treatment in EGFR-mutated NSCLC patients with brain metastases: Interim analysis of an open-label, multicenter, randomized, pivotal phase II study (ESAONA).
LBA2007 Background: Asandeutertinib (TY-9591), a novel EGFR-TKI candidate, demonstrated outstanding efficacy and manageabl...
Adjuvant sintilimab-capecitabine versus capecitabine alone in locoregionally advanced nasopharyngeal carcinoma with suboptimal response to induction chemotherapy: An open-label, randomized, controlled, phase 2 trial.
LBA6005 Background: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is the current standard tr...
A multicenter randomized phase II trial of AHCC combined with multidisciplinary treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma (jRCTs051200029).
LBA4226 Background: Malnutrition, impaired immunity, and limited tolerance to intensive chemotherapy remain major challeng...
Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
LBA8500 Background: Sunvozertinib has been granted accelerated approval in the US and China for the treatment of patients...
NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.
LBA100 Background: MCED blood tests can detect a shared cancer signal from circulating cell-free DNA. NHS-Galleri (NCT0561...
First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
LBA5003 Background: Circulating miR371 has been reported in retrospective studies as a biomarker with high accuracy for pr...
Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.
LBA1006 Background: The combination of endocrine therapy (ET) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is th...
Pathological complete response and ctDNA analyses in SCIENCE: Results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy in resectable locally advanced esophageal squamous cell carcinoma.
LBA4082 Background: The optimal neoadjuvant strategy for resectable locally advanced esophageal squamous cell carcinoma (R...